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Abstract
Background: Hearing and vision impairments are highly prevalent in people with dementia and may have a negative
impact on quality of life and other dementia-related outcomes. Intervening to optimise sensory impairment and support
sensory function may be a means of improving dementia-related outcomes. The SENSE-Cog trial will test whether a
home-based multi-part sensory intervention is effective in improving quality of life and other key outcomes in people
with dementia and hearing or vision problems (or both) and their companions.
Methods: This is an European, multi-centre, observer-blind, pragmatic, randomised controlled trial. Three hundred fifty
four people with dementia and hearing or vision impairment (or both) and their companions will be randomly assigned
to receive either “care as usual” or a multi-component sensory intervention including assessment and correction of
hearing or vision impairments (or both), home-based (maximum 10 visits over 18 weeks), therapist-delivered sensory
support (that is, adherence to devices; improving the sensory environment (that is, lighting), communication training, and
sign-posting to other support agencies). Change from baseline to intervention end (18 weeks) and post-intervention
(36 weeks) will be compared between the two arms in the following outcomes: quality of life (primary endpoint), sensory
and cognitive functional ability, relationships, mental well-being, health resource utilisation and cost-effectiveness.
Discussion: This is one of two articles outlining the SENSE-Cog trial. Here, we describe the protocol for the effectiveness
of the SENSE-Cog intervention. A parallel and complementary process evaluation will be described elsewhere. If the
SENSE-Cog trial demonstrates that the sensory intervention improves outcomes in dementia, we will make a toolkit of
training materials, resources and information available to health and social care providers to implement the intervention
in routine practice. This will be a significant contribution to the therapeutic management of people with dementia and
sensory impairment.
Trial registration: ISRCTN (Trial ID: ISRCTN17056211) on 19 February 2018.
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Background
The prevalence of dementia in Europe is high and rising;
nearly 10.5 million Europeans are currently diagnosed
with dementia [1]. Age-acquired hearing impairment or
age-acquired vision impairment or both affect one in
three Europeans [2]. People with dementia (PwD) are
more likely to experience sight loss [3] and are more
likely to self-report hearing difficulties [4] than their
cognitively healthy, senior counterparts. Thus, the likeli-
hood of co-morbid vision or hearing impairment (or
both) is a very real possibility for PwD in Europe [5].
Later-life peripheral hearing loss has been newly iden-
tified as a potential risk factor for dementia [6] and may
be modifiable through the use of hearing aids [7, 8], al-
though the evidence for this is still accruing [9]. Further-
more, improving or reversing sensory impairment in
PwD is challenging. Specifically, whereas the rate of
self-reported impairment in PwD is high, the diagnostic
rate of hearing and vision impairments is low [10].
Corrective equipment for vision [3] and hearing [11] is
not always prescribed when required, and if it is pre-
scribed, adherence is often inconsistent [12]. Thus, in
PwD with concurrent sensory problems, simply correct-
ing the impairment may be insufficient to improve
outcomes.
In cognitively healthy older people, training and sup-
port interventions to improve hearing aid adherence
[13] and home-based assessments to enhance the uptake
of glasses have been successfully implemented [14].
Moreover, it has been demonstrated that optimising
hearing can positively affect mental status [15] and cog-
nitive function [16]. Unfortunately, these studies have
not addressed similar questions in people who have been
diagnosed with dementia [11]. Despite this, there is pre-
liminary evidence that sensory remediation in dementia
is effective in reducing personal and social difficulties
when vision is improved [17], decreasing behavioural
and psychological symptoms of dementia with improved
hearing [18], reducing depression [19], and improving
cognition and mood [20]. Importantly, to be effective,
treatment should be introduced at an early stage in de-
mentia [1] and should be tailored to the specific care
needs of each individual [10]. For example, when clinical
sensory assessments with PwD are conducted, existing
vision assessments should be adapted to account for
fluctuating mental capacity, decreased executive func-
tioning, and reduced decision-making ability [3].
Optimising hearing and vision per se may not be suffi-
cient to improve outcomes for PwD. To extend a hear-
ing and vision intervention in PwD beyond just a
sensory assessment and fitting of corrective devices, fur-
ther components need to be introduced. These could
entail support from a trained therapist (that is, a “sen-
sory support therapist”, or SST), aspects of behavioural
change, and greater access to support services. Imple-
menting behavioural change can be difficult and evidence
demonstrates that behavioural changes, when attempted,
may not be sustained unless key underlying elements are
addressed [21]. There is evidence that psychosocial
interventions, introduced at an early stage of dementia,
may benefit quality of life (QoL) and other key
dementia-related outcomes [22–25]. Over the course of
18 months, guided by the UK Medical Research Council’s
framework for developing complex interventions, we used
the process of “intervention mapping” [26] to develop the
sensory intervention (SI) [26]. The SI was initially
field-trialled in the UK, France and Cyprus [27] and was
subsequently refined for full-scale trialling across five
European sites described in this article. The SI includes
the following: (1) assessment of hearing and vision func-
tion, (2) correction of hearing and vision impairments,
and (3) a home-based psycho-social intervention, encom-
passing communication training, environmental modifica-
tion, and sign-posting to further support services,
delivered by a trained therapist. To test the effectiveness
of the intervention to improve QoL in PwD with hearing
or vision impairment (or both) and their companions, we
designed the SENSE-Cog trial, which is a multi-centre,
observer-blind, pragmatic, randomised controlled study
comparing the SI with care as usual (CAU). Secondary ob-
jectives will investigate the impact of the intervention on
sensory and cognitive functional ability, the relationship of
the PwD and their companion, mental well-being, and
companion outcomes. We will also investigate health re-
source utilisation following the intervention and estimate
cost-effectiveness of the intervention.
The SENSE-Cog randomised controlled trial (RCT) is
outlined in two parts. The present article introduces the
protocol for evaluating the effectiveness of SI compared
with CAU. A separate article will outline the protocol
for the process evaluation, assessing delivery, contextual
issues and causal mechanisms of the SI.
Research question
The SENSE-Cog trial aims to address the following re-
search question: Does SI (correction of sensory impair-
ment combined with sensory support) improve the QoL
of PwD and their companions, across Europe?
The SENSE-Cog trial aims to test the following
hypotheses:
 the application of SI will enhance QoL for PwD and
sensory impairment;
 the SI will improve functional ability for the PwD
(defined by cognition-, hearing- and vision-related
activities of daily living - ADLs) and mental well-
being (defined by improved global cognitive ability,
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self-efficacy, relationship with the companion, and
reduced behavioural disturbances);
 the SI will improve mental well-being, improve the
relationship with the PwD, and reduce burden and
stress (as defined by improved companion experi-
ence, well-being and anxiety and depression) for
companions of PwD.
Methods/design
This is a 36-week, multi-centre, randomised, controlled,
pragmatic, parallel-group, observer-blind, superiority
trial comparing the effectiveness of individualised SI
with CAU on QoL and other dementia-related outcomes
in PwD with hearing or vision impairment (or both) and
their companions in five European sites. Participants will
be randomly assigned after baseline to either the SI
group or CAU group in a 1:1 ratio. The SI is composed
of three parts delivered over the course of 18 weeks: (1)
assessment of sensory impairment, (2) correction of sen-
sory impairment, and (3) SST weekly home-based visits
(maximum of 10). A subsample of 60 dyads (PwD and
their companion) in the SI group will also complete a
qualitative interview within 2 weeks of the end of the SI.
Participant selection
Participants will be recruited in “dyads” (that is, a PwD
and a companion: relative or friend) in accordance
with the criteria outlined below. Of note, a PwD with
hearing or vision impairment (or both) cannot partici-
pate if the companion is ineligible or unwilling to
participate.
Person with dementia inclusion criteria
 Is at least 60 years old;
 is diagnosed with dementia in accordance with ICD-
10 (10th revision of the International Statistical
Classification of Diseases and Related Health
Problems) criteria because of the following
conditions: Alzheimer’s disease (AD) (in
accordance with NINCDS-ADRDA [28] criteria)
or vascular dementia (VAD) (in accordance with
NINDS-AIREN [29] criteria) or “mixed” dementia
(AD + VAD);
 has dementia in the mild to moderate stage, as
indicated by a Montreal Cognitive Assessment
(MoCA) [30] score of at least 10;
 if taking cognitive enhancing medication (that is,
cholinesterase inhibitors or memantine), this must
be on a stable, unchanged dose for at least 4 weeks
prior to screening;
 has adult-acquired hearing or vision impairment (or
both) defined by
 vision impairment: defined by the presence of
 presenting binocular visual acuity of not more
than 6/9.5 and greater than 6/60 in Snellen
metric (or at least + 0.2 logMAR [75 EDTRS
Score] and less than + 1.0 logMAR [35 EDTRS
Score]) using the Portable Eye Examination
Kit (PEEK) vision tool [31] and
 visual field greater than 10° using confrontation
visual field test [32]
and/or
 Hearing impairment: defined by a bilateral hearing
difficulty, indicated by failure of a pure tone
hearing screening test in both ears, defined by
hearing worse than 35 dBHL at 1000 Hz and
above in the better ear, using the HearCheck
device [33];
 lives in an ordinary community dwelling (including
sheltered and very sheltered accommodation);
 is willing to accept SI;
 has a companion who fulfils the criteria below and is
willing to participate in the study;
 has the capacity to provide informed consent to
participate in the study or, if lacking that capacity,
has a nominated consultee to provide consent on
their behalf;
 speaks and understands the language of the
intervention delivery, as determined by the
investigator;
 is affiliated with a social security system (for France).
Person with dementia exclusion criteria
 Has an unstable, acute or current psychiatric or
physical condition severe enough to prevent them
from participating in the study, as determined by the
investigator;
 has complete blindness or severe visual impairment
(category 2 and more on ICD-10) [34] or deafness
(profound hearing loss) that will prevent them from
following study procedures;
 is currently participating in any other trial of a
potentially cognition-enhancing intervention, ex-
cluding marketed cognition-enhancing
medication;
 has scheduled or urgent treatment or intervention
for hearing or vision impairment (that is, cataract
operation already scheduled or treatment for
macular degeneration is needed);
 is unable to read and write.
Regan et al. Trials           (2019) 20:80 Page 3 of 15
Companion inclusion criteria
 Is at least 18 years old;
 is an informal caregiver (where providing care is not
the person’s primary paid role), such as a significant
other of the PwD (for example, a family member or
close friend), who is either co-resident or in regular
contact (on at least a weekly basis);
 is willing to participate in the study;
 speaks and understands the language of intervention
delivery, as determined by the investigator;
 is affiliated with a social security system (for France).
Companion exclusion criteria
 Has an unstable, acute or current psychiatric or
physical condition severe enough to prevent them
from participating in the study, as determined by the
investigator;
 is unable to read and write.
Sensory intervention
The three parts of the SI are described as follows:
Stage 1: Assessment of sensory impairment
A full vision or hearing assessment (or both) will be
undertaken by an audiologist, optometrist or ophthal-
mologist, in accordance with clinically regulated, stan-
dardised procedures (Table 1), in the participant’s home
or in the clinic within 8 weeks after randomisation.
Should medical management of cataracts or macular de-
generation be identified, participants will remain in the
study and the SI will be offered within an 18-week
period, which does not interfere with scheduled surgery.
Stage 2: Correction of sensory impairment
Glasses or hearing aids (or both) will be prescribed,
administered and fitted to participants, according to
their needs, by vision specialists (optometrist, ophthal-
mologist or optician) and audiologists, respectively, in
the participant’s home or in the clinic within 6 weeks
after full assessment (stage 1). Essilor International [35]
will provide the glasses lenses and yellow filters for the
study. Starkey Hearing Technologies [36] will provide
the hearing aids and two pocket talkers (http://
www.starkey.co.uk/hearing-aids/hearing-amplifiers) per
site. The hearing devices used for this trial will be
behind-the-ear (BTE)-style hearing instruments (specif-
ically, Starkey Muse i2400 Mini BTEs in silver). Supple-
mentary sensory devices (lamps and glasses straps) may
be supplied according to participant needs by the SST
throughout the SI (Table 2).
Stage 3: Sensory support
The SST will support participants with the following
'primary' (all participants receive) and 'secondary' (re-
ceived if needed by individual) components across a max-
imum of 10 visits over 18 weeks after randomisation (see
Fig. 1):
Continuous training in correct use of sensory devices
(primary component)
The SST will support correct wear and care of partici-
pant’s glasses and hearing aids (for example, cleaning
and storage, battery changing, and frequency of use).
The Hearing Aid Skills and Knowledge (HASK) test [37]
and SENSE-Cog Glasses Skills and knowledge test for vi-
sion alongside a SENSE-Cog functional assessment (a
non-standardised assessment developed by the research
team) [27] will be completed to monitor participant abil-
ities to manage their sensory equipment.
Table 1 Clinical audiology and ophthalmology examination procedures
Audiology examination Ophthalmological examination
Otoscopy: examination of the pinna (outer ear) and external auditory
meatus (ear canal) using British Society of Audiology (BSA)-
recommended procedure for otoscopy (British Society of
Audiology, 2010)
Observation of eyes and adnexae for any pathology, visual field testing
(using confrontation test and amsler grid for screening major visual field
deficits), and intraocular pressure measures to detect any ocular pathology
Ambient noise: background noise checks should be made prior to and
during audiometric testing to ensure that noise levels do not go over
the recommended level of 35 dBA as stated in the BSA-recommended
procedure (40 dBA maximum) for pure tone air conduction and bone
conduction threshold audiometry with and without masking.
Current optical correction: determination of lens type and power with
associated distance and near visual acuity, used as baseline visual
performance
Pure tone audiometry: air conduction and bone conduction according to
BSA-recommended procedures for pure tone air conduction and bone
conduction threshold audiometry
Visual needs: Identification of main activities with associated distance and
global light sensitivity to make refraction at appropriate distance;
recommendation of any adaptive equipment to cover unmet visual needs
Glasgow Hearing Aid Benefit Profile (GHABP) [41] Visual function evaluation: ascertainment of subjective refraction (or
objective when, owing to factors such as poor cooperation, subjective is
not possible) with associated visual acuity, contrast sensitivity, and
binocular vision
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Supporting progress towards individualised goals (primary
component)
The SST will incorporate the results of the hearing,
vision and daily living functional assessments to set
individual goals by using the Bangor Goal Setting
Inventory [38]. A maximum of three goals will be
set with participants and at least one of these goals
will explicitly include the use of their corrective
sensory device(s). Goals will typically be revisited on
a weekly basis, and the SST will explore facilitators,
barriers and resources to the goals and introduce
skills and strategies to support progress. Goal at-
tainment and performance will be re-rated by the
participant and their companion on completion of
the SI.
Enhancing communication between the PwD and their
companion (primary component)
The SST will work with the participant dyads on im-
proving communication by using the SENSE-Cog Com-
munications Manual. This information has been adapted
from existing, evidence-based resources relating to
sight/hearing loss and dementia to provide guidance and
strategies to enhance communication in different set-
tings. Copies of pre-existing materials such as leaflets
will be provided to the participants.
Accessing relevant support services (such as psychological
services) by referral (secondary component)
This may include psychological services, geriatric psych-
iatry services, falls clinics, or other health or social care
Fig. 1 The SENSE-Cog Randomised Controlled Trial Sensory Intervention: Support components delivered by the sensory support therapist
Table 2 SENSE-Cog Randomised Controlled Trial Sensory Intervention sensory devices to be supplied, who pays costs and duration
Device Supplier Cost Duration
Hearing aid: Muse i2400 Mini Behind
the ear
Starkey Hearing Technologies Free to participant Participant keeps during and
after study
Personal listening amplifier Accredited supplier such as Mini
Tech, Pocket Talker, or equivalent
Free to participant Return after study and option
to purchase at participant’s
own expense
Additional auditory or visual equipment as
advised by the sensory support therapist
Starkey Hearing Technologies or
other specialist suppliers
Participant’s own expense Participant keeps during and
after study
Glasses lenses (including yellow filters
if needed)
Essillor International Free to participant Participant keeps during and
after study
Glasses frames (participant choice) Local optician Free basic frames or other frames
at participant’s own expense
Participant keeps during and
after study
Lamp Any supplier provided that the
required criteria are met
Free to participant Return after study and option
to purchase at participant’s
own expense
Glasses straps Croakies or equivalent supplier Free to participant Participant keeps during and
after study
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services beyond the remit of the SENSE-Cog study. The
SST will identify the participant’s requirements through
the functional assessments and goal-setting exercise.
Fostering social inclusion through hobbies, interests and
groups (secondary component)
The SST will provide information and guidance to par-
ticipants about opportunities to develop their own hob-
bies and interests or attend local groups in line with
participant goals.
Guidance about supplementary sensory devices (secondary
component)
Participants with vision loss will be offered the oppor-
tunity to trial a lamp to assist with low-vision for the
duration of the intervention. The lamp spec must pro-
vide an illuminance on a work surface at 30 cm of at
least 500 lx and ideally 1000 lx. Participants will be
provided with glasses straps if required. The SST will ex-
plore whether additional sensory devices such as a media
streaming device [39] or Hearing Amplifier (http://
www.starkey.co.uk/hearing-aids/hearing-amplifiers) would
promote a sensory-conducive home environment. Some of
these devices will be loaned to participants for the
duration of the intervention and information provided
about where they may purchase them post-SI at their
discretion (Table 2).
Re-cap and review visits
If a dyad addresses all SI components prior to the end of
18 weeks, any remaining weeks will involve further recap
and review of progress, up to a maximum of 10 SST
visits.
Care as usual
The CAU group provides a comparison with the SI
group. CAU participants will receive no additional inter-
vention other than hearing and vision screening assess-
ment. CAU participants will be informed of any
suspected hearing or visual impairment (or both) identi-
fied on screening and information sheets provided about
where they may access further support through their
general practitioner or standard routes of referral. Thus,
we except a small increase in subsequent diagnosis of
sensory impairment compared with usual care but no
effect on prescription of appropriate correction and ad-
herence. Thus, effect estimate of the SI compared with
this CAU group should be slightly decreased and conser-
vative regarding type I error rate. Differences in access
of health services between the intervention group and
CAU group will be captured by the health economic
evaluation measure (Resource Utilization in Dementia-
Lite, or RUD-Lite) [40].
Recruitment
There will be several routes for participant recruitment,
depending on the specific study site. In the UK (Man-
chester), the National Health Service (mental health or
memory assessment services) will be the first-line
sources for recruitment. Other routes to participation
will include the on-line national dementia clinical re-
search portal, ‘Join Dementia Research’ (www.joindemen-
tiaresearch.nihr.ac.uk), alongside referral from local
primary care clinics, dementia support groups and the
Alzheimer Society. In France (Nice), recruitment will be
from the Centre Mémoire de Ressource et de Recherche’s
clinical database and local primary care, neurology and
geriatric medicine clinicians. In Greece (Athens), partici-
pants will be recruited from organised dementia care
centres, the Geriatric Psychiatry Outpatient Memory
Clinic, the Nestor Psychogeriatric Association and the
Athens Alzheimer Association. In Dublin, recruitment
will be from the memory clinic at the Mercer’s Institute
for Successful Ageing, St. James’s Hospital. Finally, in
Cyprus (Nicosia), participants will be identified from de-
mentia care centres, mental health services, the Ministry
of Health and private practice.
Informed consent
This procedure will be in accordance with the national
guidance regarding informed consent and clinical
research with individuals who lack capacity in each of
the participating countries. Prior to obtaining written
consent, the researcher will ensure that the person is
fully informed about the research and take time to
answer any questions. Informed written consent will be
obtained by the researcher at the participant’s home or
in clinic before any study-specific procedure for screen-
ing. All researchers will be fully trained in Good Clinical
Practice (GCP) and mental capacity assessment skills
and follow national guidance in their respective
countries, such as the Mental Capacity Act (2005) [41]
in the UK. If a person lacks capacity, a consultee—either
a personal (family/friend) or nominated (professional)—
will be asked to deem whether it is in the PwD’s best
interests to participate.
Sample size
The trial is powered to detect a standardised effect size
of 0.267 (equivalent to a 4-point change) on the Demen-
tia Quality of Life (DEMQOL) [42] and assuming a
standard deviation of 15 points in DEMQOL [42] scores.
In this population, this effect size is equivalent to the
smallest change that could be considered clinically
meaningful. Assuming a correlation of 0.6 between base-
line and 36-week follow-up DEMQOL scores [42] and
an attrition rate of 20% at follow-up (a conservative
estimate based on the 12%–15% rates observed by
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Wenborn et al., 2008 [43]), the trial will need to recruit
354 participant dyads at baseline (177 per arm) in order
to achieve 80% power to detect the aforementioned ef-
fect size at the two-sided 5% level of significance.
Outcome measures
Primary outcome
The primary outcome will be QoL of the PwD, as rated
by the PwD directly, using DEMQOL [42], at week 36
(W36). DEMQOL is a 29-item interviewer-administered,
self-report questionnaire with good psychometric prop-
erties in persons with mild to moderate dementia (good
internal consistency and test–retest reliability and mod-
erate validity) (see Table 3) (Additional file 1).
Secondary outcomes
For the person with dementia:
 QoL assessed by DEMQOL at W18
 QoL assessed by DEMQOL Proxy, at W18 and
W36, rated by the companion
 scores of the following measures at W18 and W36:
○ functional ability, assessed by the following scales:
▪ Bristol Activities of Daily Living scale [44];
▪ Veterans Affairs Low Vision-Visual Function-
ing Questionnaire [45];
▪ Veterans Affairs Low Vision-Visual Function-
ing Questionnaire Spousal rating [45];
▪ Hearing Handicap Inventory for the
Elderly [46];
▪ Hearing Handicap Inventory for the Elderly
Spousal rating [47].
○ global cognitive functioning, using the MoCA
scale [30].
○ behavioural and psychological symptoms of
dementia, assessed by the 12-item Neuro-
psychiatric Inventory [48].
○ relationship with companion, assessed by the
Relationship Satisfaction Scale [49].
Table 3 Schedule of the SENSE-Cog randomised controlled trial, according to SPIRIT checklist. * Also during sensory support
therapist visits for those allocated to the sensory intervention group. Abbreviations: PwD participant with dementia, W week
Phone call Visit Phone call
W-2/W0 W-2/W0 W0 W0-W7 W8 W9-W18 W18 W26 W36
max. 3 days 
after baseline
+/- 2 weeks +/-2 weeks
SCREENING
Signed informed consent X
Eligibility screening X
Hearing screening X
Vision screening X
Randomisation X
INTERVENTIONS
Sensory intervention
Care as usual: booklet and referral X
ASSESSMENTS
About the PwD
Demographics and medical 
history
X X
Quality of life X X X
Functional ability X X X
Cognitive functioning X X X
Behavioral and psychological 
symptoms of dementia
X X X
Relationship with the companion X X X
Adverse and serious adverse events* X X X X
About the companion
Demographics X X
Mental well-being X X X
Quality of life X X X
Experience X X X
Relationship with the PwD X X X
Anxiety and depression X X X
Health economic outcomes
Healthcare resource utilisation X X X
Health utility X X X
About the dyad
Qualitative interview 
(only for the sensory intervention group)
As soon as possible after 
the end of the intervention
TIMEPOINT
STUDY PERIOD
Screening Baseline Randomisation
Follow-up
Final visit
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For the companion:
 mental well-being and QoL using the 12-item Gen-
eral Health Questionnaire [50] and health utility
using the Short Form-12 Health Survey [51] (Brazier
and Roberts, 2004 [51]), at W36;
 scores of the following measures at W18 and W36
○ companion experience, assessed by the Family
Caregiving Role scale [52];
○ relationship with PwD, assessed by the
Relationship Satisfaction Scale [49];
○ companion anxiety and depression, assessed by
the Hospital Anxiety and Depression scale [53].
Health economic outcomes:
 health-care resource utilisation from baseline to
W18 and W36 collected using the RUD-Lite instru-
ment [40] with the companion;
 health utility, ascertained at baseline, W18 and W36
from:
○ 5-level EuroQol 5-dimension rated by both the
PwD and the companion [54];
○ Short Form-12 Health Survey [51], rated by
both the PwD and the companion.
Demographics
Demographic information about the PwD and companion
will be captured at screening and baseline relating to age,
gender, maritial status, living status, current or former oc-
cupation, duration and type of memory problem, diagno-
sis date, years in formal education, date of most recent
hearing and vision screen, current medication for demen-
tia and current psycho-social interventions. This will allow
screening of eligible participants and will allow analysis of
the potential influence of demographic differences on out-
come variables within and between sites.
Study procedures
Timeline
 Start of inclusion period: first quarter of 2018;
 duration of the inclusion period: 21.5 months;
 duration of participation of each participant: 36 to
40 weeks (that is, around 9 to 10 months);
 total duration of the study: 33–34 months.
Initial screening visit
Cognition will be assessed by MoCA [30]. Hearing will be
screened by using “HearCheck” [33] (a simple hand-held
screening device). Vision will be screened by using the
“PEEK Acuity App” [31] alongside the confrontation vis-
ual field test: “Can you see my hands?” [32].
Baseline visit
The baseline visit is conducted at the PwD’s home or
clinic by a researcher. PwD and companion complete a
battery of scales (around 2 h) (Table 4). The baseline
visit may be conducted the same day as the screening
visit (but after the screening procedures) if the PwD and
the companion meet the eligibility criteria. This baseline
visit may also be split into two visits (depending on the
PwD or the companion’s preference). The second base-
line visit must be conducted within 2 weeks of the first
baseline visit.
Data protection and sharing
We will follow best practice in accordance with current
UK General Data Protection Regulation (GDPR) guid-
ance and adhere to the Guidelines for Data Management
in Horizon 2020 and local guidelines for each site; no
patient identifiable data (PID) will be transferred across
sites. All PID will be kept separately from the anon-
ymized data to be entered in the case report form (CRF).
The University of Manchester institutional repository
(Research Data Management Service) will cater for the
publishing and sharing of research data. Data will be
made available through the University of Manchester in-
stitutional repository (Research Data Management Ser-
vice). Research data will be made available together with
appropriate metadata in line with Horizon 2020 policy
to enable other researchers to identify whether the data
could be suitable for re-use. Published outputs will be
assigned a Digital Object Identifier to reference the data
in publications. Anonymised data will eventually be
made open access and this will also be made clear to
participants before they consent.
Randomisation and allocation concealment
Randomisation will be performed no later than 3 days fol-
lowing baseline. Randomisation will be conducted through
the trial electronic case report form (eCRF) [55]. One per-
son in each site will perform randomisation. One person
from the research team will be identified in each site to
perform randomisation, excluding the blinded researcher
who will undertake the outcome visits. Randomisation will
be stratified by centre. Once participants are allocated to
the eCRF, eligibility criteria (including signed informed
consent) must be met to allow for randomisation online.
The SST will then trigger the local procedure for sensory
assessment and provision of hearing aids/glasses for those
participants allocated to the SI group.
The randomisation code will be maintained by the
European Clinical Trials Platform & Development (EU-
CLID) Coordinating Trial Unit (CTU). The blinded
researcher and the statistician team will not have access
to the randomisation code. To ensure allocation
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concealment, full details of the randomisation scheme
will not be disclosed.
Blinding
It will not be possible for participant dyads to be blinded
to the allocation they receive on randomisation. Thus,
each centre will have both blinded and un-blinded re-
searchers involved with different aspects of the study.
The SST will not be blinded. The outcome rater (blinded
researcher) will be blinded and every attempt to main-
tain this blind will be made. To achieve this, when the
follow-up visits are booked by the SST, the participant
dyad will be reminded to make every effort not to reveal
whether they had received the intervention or not. This
will include keeping study-related materials (including
new devices such as hearing aids, special lamps or other
sensory support devices or materials) out of sight during
the outcome rating visit.
During follow-up visits, an un-blinded researcher
will administer MoCA [30] and HHIE (Hearing
Handicap Inventory for the Elderly - 25 items) [46]
with the PwD still wearing hearing aids and glasses if
required. The blinded researcher will conduct the
remainder of the measurement scales while the par-
ticipant is wearing glasses but not hearing aids. Since
most of the outcome measures will be undertaken
with the companion as informant for either them-
selves or the PwD, this should not interfere with the
integrity of the outcome measures.
For the blinded researcher, ratings will be ascer-
tained of their perception of allocation of participant
dyads to determine the strength of the allocation
concealment. At W18 and W36, blinded researchers
will rate a Likert-style scale [56] (completely certain,
somewhat certain, some doubt, not at all certain, or
complete guess) of their perception of which group
the participant dyad has been assigned to. This will
be analysed to ascertain the proportion of blinded
researchers who are correct, incorrect or neutral for
treatment allocation at W18 and W36.
Follow-up visits
At 18 weeks (± 2 weeks) and 36 weeks (± 2 weeks), re-
searchers will visit the PwD and their companion to
complete the same battery of scales as at the baseline
visit (Table 4). If a second visit is required because of
Table 4 Battery of scales administered during baseline, week 18 and week 36 visits
Outcome Administered by Information about Scale
QoL of PwD Researcher to PwD PwD DEMQOL [42]
Researcher to companion PwD DEMQOL proxy [42]
Dementia-related functional ability Companion self-completes PwD BADLs [44]
Vision-related functional ability Researcher to PwD PwD LV-VFQ – 20 [45]
Researcher to companion PwD LV-VFQ – SP
Hearing-related functional ability Researcher to PwD PwD HHIE-25 [46]
Researcher to companion PwD HHIE-SP [47]
Global cognitive functioning Researcher to PwD PwD MoCA (at screening) [30]
Behavioural and psychological symptoms Researcher to companion PwD NPI-12 [48]
Relationship with companion Researcher to PwD (not in presence
of companion)
PwD RSS [49]
Mental well-being of companion Companion self-completes Companion GHQ-12 [50]
QoL of companion Researcher to companion Companion SF-12 [51]
Companion experience Companion self-completes Companion FCS [52]
Relationship with PwD Companion self-completes Companion RSS [49]
Companion depression Companion self-completes Companion HADS [53]
Health resource utilisation Researcher to companion PwD RUD-Lite [40]
Researcher to companion PwD EQ-5D-5 L Proxy [54], SF-12 Proxy [51]
Researcher to PwD PwD EQ-5D-5 L [54], SF-12 [51]
Abbreviations: BADLs Bristol Activities of Daily Living, DEMQOL Dementia Quality of Life, EQ-5D-5 L 5-level EuroQol 5-dimension, EQ-5D-5 L-P 5-level EuroQol 5-
dimension Proxy, FCS fluorescence correlation spectroscopy, GHQ-12 General Health Questionnaire – 12 items, HADS Hospital Anxiety and Depression Scale, HHIE-
25 Hearing Handicap Inventory for the Elderly - 25 items, HHIE-SP Hearing Handicap Inventory for the Elderly Spousal rating – 25 items, LV-VFQ – 20 Veterans
Affairs Low-Vision Visual Functioning Questionnaire – 25 items, LV-VFQ – SP Veterans Affairs Low-Vision Visual Functioning Questionnaire Spousal rating – 25
items, MoCA Montreal Cognitive Assessment, NPI-12 Neuropsychiatric Inventory – 12 items, PwD people with dementia, QoL quality of life, RSS Relationship
Satisfaction Scale, RUD-Lite Resource Utilization in Dementia-Lite, SF-12 Short Form-12 Health Survey
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fatigue, this will take place within 2 weeks following the
first.
Therapist compliance with protocol
The SST will update a logbook after each SI session to
record the following: participant progress, motivation,
adherence to equipment, and emotional enagement. The
SST will have monthly individual and 3-monthly group
supervision sessions with the lead SST, who will oversee
the delivery of the intervention across the five sites. The
lead SST will review the SST logbooks to discuss at each
supervision, and particpant details will be anonymised.
Participant adherence to the intervention
Adherence to the use of sensory equipment and other
intervention procedures will be documented by the PwD
and companion in pre-printed diaries and in the SST log-
book and willl be described during the post-intervention
semi-structured interview. Details of how these data will
inform analysis of process measures will be detailed in the
process evaluation protocol article.
Analysis of Outcomes: Descriptive analyses
Continuous and ordinal variables will be described in
terms of absolute frequency, mean, standard deviation,
95% confidence interval of the mean, median, interquartile
range, and minimum and maximum. Categorical variables
will be described in terms of number, proportion and 95%
exact binomial confidence interval of proportion.
Quantitative analyses: Test of the intervention effect
For estimating and testing the effect of the intervention on
the primary (DEMQOL score at 36 weeks) and secondary
outcomes, an a priori Statistical Analysis Plan (SAP) will be
devised, detailing the analysis methods, outcomes, covari-
ates, handling of missing data, standard error estimation
methods and any sensitivity analyses. The SAP will be sub-
mitted to the Trial Steering Committee (TSC) for review
and approval prior to the start of statistical analyses.
Intention-to-treat principles will be followed, and all ran-
domly assigned participants will be analysed according to
trial arm allocation, including as far as possible those who
discontinue the study, for whom follow-up data will con-
tinue to be collected wherever possible.
A separate multi-level (participants within sites) mixed-
effects regression analysis will be conducted for each out-
come to estimate and test the mean effect of the interven-
tion at 18 and 36 weeks. In each case, the dependent
variable will be the outcome scores at baseline, 18 and
36 weeks, and covariates will be trial arm, time point and
pre-specified participant- and country-level covariates.
The tests for treatment effect at 18 and 36 weeks will be
based on the relevant component of the trial arm by
time-point interaction. Study site will be treated as a fixed
effect. The primary analysis will use complete cases only;
sensitivity analyses will assess robustness of results to con-
cerns, including non-normality (using the non-parametric
bootstrap method of standard error estimation), missing
values (using single or multiple imputation as appropriate)
and baseline imbalance (by inclusion of unbalanced covar-
iates). Between-site heterogeneity in treatment effects will
be explored by using moderator analysis. The statistics
team at Manchester University will conduct all analyses
using Stata statistical software [57]. All statistical tests will
be performed with a two-sided type I error rate of 5%.
Qualitative interview analyses
All interviews with dyads allocated to the SI group will be
audio-recorded, transcribed verbatim and anonymised.
The interviews will be analysed by using conventional
qualitative content analysis [58] and a Grounded Theory
approach [59]. Qualitative analysis of the post-SI inter-
views will be led by the Catholic University of Applied
Sciences Freiburg (CUF). Researchers at respective sites
will identify initial themes in their native language. CUF
will then combine the whole dataset and generate a final
code list using Grounded Theory (Glaser and Strauss,
1967 [59]) methodology. This will be through an iterative
process of data collection and analysis to develop initial
themes, prior to analysing the entire data set and develop-
ing a model based on emerging categories. Key themes
and quotations will be selected for translation into English
from native languages. QDA software will be used
(MaxQDA) [60] to keep transcripts and quotes in respect-
ive native languages during the whole analysis process.
The participant diaries will be used by the SST to inform
and shape their intervention plan. At the end of the study,
the diaries will be analysed in relation to the process mea-
sures of the trial, reported in a separate article.
Health economic analysis
A within-trial cost-effectiveness analysis will be per-
formed. All costs consumed and quality-adjusted
life-years (QALYs) gained within the 36 weeks of the
trial will be calculated for both the SI group and the
CAU group. Costs will be estimated on the basis of the
resource use data collected in the trial and applying unit
costs from country-specific reports and the published lit-
erature. The health utility scores will be multiplied by
the duration of time spent on each health state to gener-
ate QALYs. The incremental cost-effectiveness ratios of
the SI compared with CAU will then be calculated.
A model-based cost-effectiveness analysis will be con-
ducted to estimate costs and effects. Parameters in the
model will be specified using data collected within the
trial, published literature, or expert opinion. In the ana-
lysis, the impact of parameter uncertainty will be explored
in one-way sensitivity analysis on each parameter and
Regan et al. Trials           (2019) 20:80 Page 10 of 15
probabilistic sensitivity analysis using a Monte Carlo
simulation with 1000 iterations. A cost-effectiveness ac-
ceptability curve will be used to describe the probability
that the cost per QALY gained from the analysis is
cost-effective for a range of levels of willingness to pay of
the decision maker (their ceiling cost-effectiveness ratio).
The net benefit will be estimated at the willingness-to-pay
threshold for each country, respectively.
Study governance
EARB composition and role
The two main missions of the Ethical Advisory and Re-
view Board (EARB) are to review adverse events/serious
adverse events (AEs/SAEs) that may occur during the
trial and to give ethical input through its independent
chair. The role of the EARB is also to provide advice,
through its chair, to the TSC, Trial Management Team
(TMT) and any funder on the above aspects of the trial.
The members are appointed by the coordinating inves-
tigator on behalf of lead organisation of the trial (Uni-
versity of Manchester). Membership consists of a chair,
the principal investigator (PI) of each of the five study
sites, the local sponsor or representative from each site,
and a representative from EUCLID.
The TSC will oversee all aspects of the design, conduct,
management, reporting and dissemination of the trial. It
will be composed of independent members, the chair of
the EARB, site representatives, statisticians, methodolo-
gists, project coordinator and devices suppliers.
EARB and TSC will ensure the highest standards of
clinical research, covering scientific quality, ethical
standards and all related management issues, in com-
pliance with GCP. The trial will adhere to GCP and
standard operating procedures (SOPs) of SENSE-Cog
for all trial and data management, statistical and
regulatory matters. All research staff (participant fa-
cing) will undergo training in GCP (or equivalent
accredited standards at their local site) with regard to
the conduct of clinical trials. Trial-specific training
will be delivered to all research and sensory support
staff prior to the start of the study.
A TMT (chief investigator, statisticians, methodolo-
gists, project coordinator, clinical research associates,
data manager and any relevant participants to discuss
specific issues) will undertake the day-to-day manage-
ment of the study. The EARB, TSC and TMT will
regularly interact to ensure a smooth trial conduct.
Safety
As the study is low-risk, a formal Data Monitoring Com-
mittee is not necessary. Instead, the EARB will review on
a regular basis (monthly initially) AEs and SAEs and their
relatedness with study intervention. Any decision to stop
the trial will be made in conjunction with the TSC.
There is a small risk of falls when introducing new
glasses. Therefore, the optometrist or vision specialist
will introduce the glasses step-wise where necessary.
Consistent and thorough checking by the SST will occur
to ensure that visual devices are appropriate and, where
inappropriate, will refer back to clinical services to refine
the prescription. The SI up to 18 weeks may be a large
commitment for some participants, so we will make
clear the benefit to them and be flexible around partici-
pant availability for the SI visits.
Each local sponsor will ensure that the appropriate in-
surance and indemnities are adhered to in accordance
with national guidelines to ensure that the highest stand-
ard of safety is maintained and that thorough safety
monitoring is undertaken throughout the trial. This
process will follow a trial-specific SOP for reporting AEs
and SAEs. SAEs will be notified to the coordinating in-
vestigator, the local sponsor and EUCLID in accordance
with a specific reporting time frame. Each local investi-
gator and site staff will be responsible for detecting, doc-
umenting and reporting AEs or SAEs. AEs and SAEs
will be reviewed on the whole during EARB meetings
(initially monthly and at least every 6 months) and TSC
meetings (annually). AEs and SAEs will be collected
from the date the consent form is signed and up to 1
month after the planned end of participant follow-up
when this could be due to the study. A phone call to
both groups will assess AEs and SAEs at weeks 8 and 26.
After the initial AE/SAE report, the local investigator will
follow up the participant until the event has resolved or
the participant is lost to follow-up. Additionally, the inten-
sity and causality of each AE will be classified by the local
site PI according to severity. The local site PI will use their
clinical judgement to determine the relationship between
the SI or the trial and the occurrence of each AE/SAE. In
this process, the natural history of the underlying condi-
tion, concomitant treatments, other risk factors, and the
temporal relationship to the AE/SAE to the study SI will
be considered. The local site PI will determine whether an
SAE is expected or not.
Data management of the RCT
Different tasks of data management (from study design
to database closure) and the responsibilities of each per-
son involved in the data management process and qual-
ity control are detailed in a data management plan. Data
are collected by using an eCRF (screening, baseline and
follow-up data); diaries, completed by PwD and their
companion (to assess whether the intervention is accept-
able, tolerated, helpful and useful and to include any
comments relevant to the intervention components or
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delivery); a logbook (SI data), completed by the SST; and
qualitative interviews, audio-recorded.
Any original document or information recorded dur-
ing the study is defined as a source document and the
eCRF must accurately reflect the data in the source
document. Source document in the framework of the
study can be paper CRF, original copy of scales or med-
ical files.
Consistency checks will be programmed by the data
manager to check the consistency and the completion of
data in the eCRF. The list of consistency checks will be
predefined by the project team and passed on to the data
manager who will write a study-specific data validation
plan. Additional queries might also be raised by the clin-
ical research assistant. Queries are sent to the clinical site
via the eCRF. The data manager will complete self-evident
corrections (SECs) in the database following rules defined
in the SEC plan validated and signed by the sponsors and
the investigators before implementation. Remote and
onsite monitoring is organised throughout the trial to en-
sure compliance to the protocol, regulations and GCP
recommendations.
Dissemination policy
Results of the RCT will be submitted for publication in a
peer-reviewed journal, and priority will be given to
open-access publications, and presentations of key re-
sults will be made at local, national and international
conferences in relevant fields. Feedback on study out-
comes will be offered to study participants, our research
user group (RUG), and the lay public by using various
formats (on-line, print material, and lectures), including
the SENSE-COG website (https://www.sense-cog.eu/), in
all five countries involved.
Patient and public voice
Informed by principles of public involvement in research
[61], the SI development involved a co-operative ap-
proach with “patient and public voice” (PPV) members
at each stage during the field trial [27]. This was con-
ducted with SENSE-Cog RUG in each of the study sites.
Details of the PPV RUG training and contributions are
outlined in a separate report [62].
Provisions for ancillary and post-trial care
For each site, local arrangements with partner clinical
services are in place to manage post-trial care; spe-
cific compensation for harm is incorporated within
each local site’s sponsor agreements and liability ar-
rangements, which differ at each site, according to
the sponsoring organization.
Local sponsors
There is no primary sponsor. Each site will have a local
sponsor responsible for governance and research con-
duct at that site. Local sponsor details are as follows:
Research governance sponsor representative,
Manchester, UK: Lynne MacRae,
University of Manchester, Simon Building, Oxford
Road, Manchester, UK
M13 9PL, phone: + 44(0)161275 5436, email:
lynne.macrae@manchester.ac.uk;
Local sponsor representative, Athens, Greece: Antonios
Politis, 1st Department of Psychiatry, Division of
Geriatric Psychiatry, Eginition Hospital National and
Kapodistrian, University of Athens, 74 Vas. Sophias
Avenue, 11,528, Athens, Greece, phone: (+ 30) 21 07 28
92 72, email: apolitis@med.uoa.gr;
Local sponsor representative, Dublin, Ireland: Ann
Dalton, St. James’s Hospital James’s Street, Dublin,
Ireland, email: CEOPA@stjames.ie;
Local sponsor representative, Nice, France: Eric
Monch, University Hospital of Nice
Cimiez Hospital, 4 avenue Reine Victoria - BP 1179,
06003 Nice Cedex 1, phone: 33 (0)4 92 03 40 11, email:
monch.e@chu-nice.fr;
Local sponsor representative, Nicosia, Cyprus: Fofi
Constantinidou,
Center for Applied Neuroscience and Department of
Psychology, Kallipoleos 75, University of Cyprus,
Nicosia 1678, Cyprus, phone: + 357 22 89 2078, email:
fofic@ucy.ac.cy.
Authorship eligibility guidelines and any intended use of
professional writers
No professional writers are planned. Authorship will
follow standard guidelines for attribution and respon-
sibility for content and will be monitored through the
TMT and then the TSC and ultimately through the
full SENSE-Cog programme’s Steering Committee,
which includes representation of all of the consortium
partners.
Plans for communicating important protocol
modifications
In accordance with local research ethics committee/in-
stitutional review board (REC/IRB) requirements, this
will be conducted under the rubric of “major” and
“minor” amendments; no changes will be acted upon
until the amendments have been accepted at all sites.
Interim analyses and stopping guidelines
Since this is a very-low-risk RCT, there is no data
monitoring and ethics committee (DMEC) and no
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interim analysis is planned for either safety or futility
analysis.
Public access to the full protocol, participant-level
dataset, and statistical code
The full protocol will be communicated with primary
publication of study results (and statistical code depend-
ing on the journal), and participant-level dataset (and
statistical code) will be accessible through request to the
EARB.
Data transfer
The conditions for data transfer of all or part of the
study database will be decided by the EARB and will be
the subject of a written contract. We will deposit data
on the Dementias Platform UK (DPUK) databank.
Criteria for discontinuing or modifying allocated
interventions for a given trial participant
Since this is a very-low-risk RCT, it is unlikely that the
intervention will have to be discontinued, but modifica-
tion of how the intervention will be delivered will be
participant-specific since this is a pragmatic, tailored
intervention with no specific dosing, aside from the
recommended number of therapist visits. Decisions
on how to modify the intervention will be taken by
the therapist delivering the intervention, supervised
by the senior sensory therapist in regular 1:1 supervi-
sion sessions and group oversight sessions (with all
the site therapists). If any participant withdraws con-
sent or experiences an SAE, they will be withdrawn
from the study.
Discussion
The main strength of the SENSE-Cog RCT is that it is the
first trial to evaluate a complex intervention for sensory cor-
rection and support for PwD on a European scale and with a
parallel process evaluation. This will enable the research
team to understand results, delivery, context issues and
causal mechanisms. The sample size will enable us to high-
light a clinically relevant difference in DEMQOL analysis.
The main limits of the trial are the inter-country biases,
which may affect the data. Furthermore, owing to the
patient-reported nature of the intervention, the study is
not double-blinded. We anticipate that there may be chal-
lenges to recruitment if participants do not identify them-
selves as having sensory impairment. There have been
some time delays to setting up the project and completing
the field trial [27] as a result of developing consistent pro-
cesses across different European countries with respective
health systems. This rigorous approach to set-up aims to
set the foundation for a robust RCT.
If following trial completion the SI does demonstrate
improvement in QoL, the aim is to develop a toolkit of
training materials, resources and information to be avail-
able to health and social care providers to implement in
routine practice. This may offer a viable therapeutic tool
for sensory remediation for people living with dementia
and sight or hearing loss across Europe. Finally, we aim
to be able to describe the entire programme of work of
the SENSE-Cog H2020 in the context of the SENSE-Cog
RCT.
Trial status
The article is based on the SENSE-Cog RCT protocol
version 3.0 of 22 January 2018. The SENSE-Cog
programme, of which the RCT is one work package,
began on 1 January 2016. Recruitment started on 30
April 2018 in the UK, and the first participant has
been recruited in the UK. The end date for the trial
follow-up is planned on 31 December 2020.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 123 kb)
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